'Reckless' Adviser Doomed Copy Of Biogen Blockbuster: Suit
The "reckless indifference" of a prominent pharmaceutical adviser cost a generic-drug maker exclusive rights to sell a copy of Biogen Inc.'s blockbuster multiple sclerosis drug Tecfidera, according to a new lawsuit...To view the full article, register now.
Already a subscriber? Click here to view full article